Drug Delivery News and Research RSS Feed - Drug Delivery News and Research

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.
BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight receives CE Mark approval for CellDetect bladder cancer test

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that its CellDetect non-invasive test for detecting bladder cancer in urine has obtained CE Marking, enabling the product to be marketed and sold in Europe and other territories. [More]
Oramed Pharmaceuticals submits study protocol to FDA for Phase IIb trial of ORMD-0801

Oramed Pharmaceuticals submits study protocol to FDA for Phase IIb trial of ORMD-0801

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has submitted the study protocol for the company's Phase IIb trial of ORMD-0801, its oral insulin capsule, to the U.S. Food and Drug Administration. [More]
Tris, Pfizer Consumer Healthcare sign agreement to market extended-release Robitussin for treatment of cough

Tris, Pfizer Consumer Healthcare sign agreement to market extended-release Robitussin for treatment of cough

Tris Pharma, Inc. today announced that it has entered into a license, supply, and distribution agreement with Pfizer Consumer Healthcare. [More]
iCo Therapeutics declares voting and election results from its 2015 Annual Meeting of Shareholders

iCo Therapeutics declares voting and election results from its 2015 Annual Meeting of Shareholders

iCo Therapeutics, today announced that all nominees listed in the management information circular dated June 1, 2015 were elected as directors at its 2015 Annual Meeting of Shareholders, held earlier today, June 26 2015. [More]
Cannabis and Cannabinoid Research journal supports President Obama's statement on medical use of marijuana

Cannabis and Cannabinoid Research journal supports President Obama's statement on medical use of marijuana

Mary Ann Liebert, publisher of the newly launched peer-reviewed open access journal Cannabis and Cannabinoid Research, strongly supports President Obama's statement that "...carefully prescribed medical use of marijuana may in fact be appropriate and we should follow the science as opposed to ideology on this issue," when asked about a pending Senate bill seeking to change federal law regarding state-legalized medical marijuana programs. [More]
IU researchers find that microRNA-29 may be potent therapeutic target against pancreatic cancer

IU researchers find that microRNA-29 may be potent therapeutic target against pancreatic cancer

Indiana University cancer researchers found that a particular microRNA may be a potent therapeutic agent against pancreatic cancer. The research was published June 22 in the journal Scientific Reports. [More]
Impax Laboratories prices convertible senior notes due 2022 in private offering

Impax Laboratories prices convertible senior notes due 2022 in private offering

Impax Laboratories, Inc. priced $500,000,000 aggregate principal amount of 2.00% convertible senior notes due 2022 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). [More]

Inhaler testing brochure released by Copley Scientific

A new brochure from Copley Scientific offers comprehensive, authoritative guidance to support the development of optimal testing strategies for new and generic orally inhaled and nasal drug products (OINDPs). ‘Quality Solutions for Inhaler Testing, 2015 Edition’ includes detailed information on regulatory requirements and highlights pertinent new additions to the company’s extensive inhaled product testing range. It can be downloaded freely from the Copley Scientific website (www.copleyscientific.com) with print versions available on request from sales@copleyscientific.co.uk. [More]
Researchers develop new implantable drug-delivery system using nanowire

Researchers develop new implantable drug-delivery system using nanowire

A team of researchers has created a new implantable drug-delivery system using nanowires that can be wirelessly controlled. [More]

Picosun provides advanced ALD coating solutions to enhance medical technology

Picosun Oy, the leading supplier of high quality Atomic Layer Deposition (ALD) technology for industrial manufacturing, provides the advanced ALD coating solutions to enable the next generation of cutting-edge medical technology. [More]
Scientists explain the existence of intrinsic chirality in ordinary nanocrystals

Scientists explain the existence of intrinsic chirality in ordinary nanocrystals

A team of scientists from ITMO University and Trinity College Dublin published first experimental results showing that ordinary nanocrystals possess intrinsic chirality and can be produced under normal conditions as a half-and-half mixture of mirror images of each other. [More]
Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases

Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases

The Johns Hopkins University and Bayer HealthCare have entered into a five-year collaboration agreement to jointly develop new ophthalmic therapies targeting retinal diseases. The goal of the strategic research alliance is to accelerate the translation of innovative approaches from the laboratory to the clinic, ultimately offering patients new treatment options for several retinal diseases. [More]
CQDM, OCE grant $1.5M to speed up drug discovery and development in Quebec-Ontario Life Sciences Corridor

CQDM, OCE grant $1.5M to speed up drug discovery and development in Quebec-Ontario Life Sciences Corridor

CQDM and Ontario Centres of Excellence will fund five highly innovative and unconventional game-changing research and development projects to accelerate drug discovery in the Quebec-Ontario Life Sciences Corridor. Partners are granting $1.5M to Quebec-based and, for the first time, Ontario-based researchers thanks to the partnership with OCE through CQDM's 2014 Explore Program, one of CQDM's flagship programs focusing on early concept validation of cutting-edge technologies that address the most crucial needs in drug discovery and development. [More]
West Pharmaceutical Services hosts groundbreaking ceremony for new manufacturing facility in Ireland

West Pharmaceutical Services hosts groundbreaking ceremony for new manufacturing facility in Ireland

West Pharmaceutical Services, Inc., a global leader in innovative packaging components and drug delivery systems, hosted a groundbreaking ceremony in Waterford, Ireland today to mark the start of construction for the company's new pharmaceutical component manufacturing facility. Attended by Cllr James Tobin, Mayor of Waterford City and County; Cllr Lola O'Sullivan, Mayor of Waterford Metropolitan District; and other local officials, the event celebrated West's continued investment in Ireland and commitment to the local Waterford community. [More]
BioLight expands relationship with Ora to develop TeaRx multi-parameter diagnostic test for DES

BioLight expands relationship with Ora to develop TeaRx multi-parameter diagnostic test for DES

BioLight Life Sciences Investments, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced that it has expanded its relationship with Ora, Inc., a world-leading independent, full-service ophthalmic contract research organization and product development firm, via the signing of a Collaboration Agreement (the "Agreement") pursuant to which the companies will work together to advance the clinical, regulatory and commercial development of BioLight's TeaRx multi-parameter diagnostic test for dry eye syndrome ("DES"). [More]
Scientists and clinicians from across the UK come together to address treatment of brain tumors

Scientists and clinicians from across the UK come together to address treatment of brain tumors

In an exciting step forward to finding a cure for brain tumours, which kill more children and adults under the age of 40 than any other cancer, the national charity Brain Tumour Research brought together a group of leading brain tumour scientists and clinicians to help accelerate vital research into this devastating disease. [More]
WellSpan Health, CareFusion announce successful implementation of Alaris System in WellSpan hospitals

WellSpan Health, CareFusion announce successful implementation of Alaris System in WellSpan hospitals

WellSpan Health and CareFusion, a BD company, today announced the successful implementation of the Alaris System across all four WellSpan hospitals, with WellSpan York Hospital becoming the first hospital ever to simultaneously go-live with new infusion devices and bi-directional interoperability between the infusion device and the electronic health record (EHR). [More]

Researchers develop mesoporous particles for use as drug delivery system

A research group led by MANA Scientist Kohsaku Kawakami, postdoctoral researcher Shaoling Zhang and MANA Principal Investigator Katsuhiko Ariga, at the International Center for Materials Nanoarchitectonics (MANA), NIMS (Sukekatsu Ushioda, President), succeeded in developing porous particles (mesoporous particles) consisting solely of phospholipids, a biological component, that are suitable for use as a drug delivery system. [More]
Scientists study crystallisation process to find new ways to produce pharmaceuticals

Scientists study crystallisation process to find new ways to produce pharmaceuticals

Scientists from across the UK and Europe are working together to build a better understanding of the chemical processes behind the creation of crystals with the aim of developing new ways to produce pharmaceuticals. [More]
Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Stemedica receives FDA's IND approval for itMSC Phase IIa clinical trial to treat Alzheimer's disease

Stemedica Cell Technologies, Inc. received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD), the sixth leading cause of death in the United States. [More]
Advertisement
Advertisement